Abstract:Yan-Yan Hao, 1, 2, &ast Yi-Peng Qiao, 3, &ast Jian-De Cheng 1, 2 1 Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, People's Republic of China; 2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, People's Republic of China; 3 Department of Internal Medicine, Qing-Xu County People's Hospital, Taiyuan, 030499, Shanxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jian-De Cheng Department of Respiratory and Critical Medicine of Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, People's Republic of China Tel +86 13834668789 Email Objective: Anlotinib was the standard monotherapy for patients with previously treated small cell lung cancer (SCLC) in recent years. Programmed cell death protein 1 (PD-1) blockade combined with antiangiogenic targeted drugs have proved to play a synergistic action for cancer treatment clinically. Consequently, the present study was to investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with previously treated SCLC. Methods: A total of 36 patients with SCLC who were treated with at least one previous systemic chemotherapy regimen participated in this study retrospectively. All the patients were administered with anlotinib plus PD-1 blockades therapy. Clinical activity was assessed according to the change of target lesion by imaging evidence and all the subjects were followed up regularly. Safety profiles were collected and documented during the treatment. Univariate analysis was carried out using Log rank test and multivariate analysis was adjusted by Cox regression analysis. Results: All the 36 patients with previously treated SCLC were able to have their efficacy and safety profile evaluated. The best overall response of the combination regimen showed that complete response was observed in one patient, partial response was noted in 9 patients, stable disease was reported in 19 patients, progressive disease was seen in 7 patients. Therefore, the objective response rate (ORR) of the 36 patients was 27.8% (95% CI: 14.2– 45.2%), disease control rate (DCR) was 80.6% (95% CI: 64.0– 91.8%). Regarding the prognostic data, the median PFS and OS of the 36 patients was 4.6 months (95% CI: 3.13– 6.07) and 9.3 months (95% CI: 3.30– 15.30), respectively. The most common treatment-related adverse reactions were hypertension (52.8%), fatigue (47.2%), diarrhea (38.9%), hand and foot reaction (38.9%) and dermal toxicity (33.3%). Furthermore, multivariate Cox regression analysis for PFS indicated that ECOG performance status was an independent factor to predict PFS. Conclusion: Anlotinib combined with PD-1 blockades regimen preliminarily demonstrated encouraging efficacy and tolerable safety for patients with previously treated SCLC. The conclusion should be validated in prospective clinical trials subsequently. Keywords: small cell lung cancer, anlotinib, PD-1 blockade, efficacy, safety As an aggressive and devastating malignancy, small cell lung cancer (SCLC) is characterized by rapid growth and early metastasis, and accounts for approximately 15% of all diagnosed lung cancers. 1 The estimated prevalence of SCLC was approximately 122,000 new cases and 107,000 new deaths of SCLC in China annually. 2 Almost 70% of the patients with SCLC presented with extensive-stage SCLC (ES-SCLC), which was of dismal prognosis with the 5-year survival rate <3% and median overall survival (OS) of <12 months. 3 To our knowledge, after the failure for first-line regimen of etoposide plus platinum doublet chemotherapy, topotecan remained the recommended second-line treatment in China with the median duration of response only 3 months. 4 Therefore, effective regimens with tolerable safety profile as second-line and above therapy for patients with ES-SCLC are needed currently. It was reported that approximately 80% of SCLC was associated with positive vascular endothelial growth factor (VEGF) expression. 5 Therefore, antiangiogenic targeted drugs demonstrated encouraging efficacy for patients with ES-SCLC recently. 6 Additionally, anlotinib was reported to improve PFS and OS dramatically in a phase II clinical trial (ALTER1202) for patients with SCLC. 7 Consequently, anlotinib had become the standard regimen as third-line mono -Abstract Truncated-

Abstract 675: Targeting Bcl-2/Bcl-xl for small cell lung cancer treatment with LP-118

Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia

Abstract B72: Combining Immune Checkpoint Inhibition and DNA Damage Repair (DDR) Targeted Therapy in Small Cell Lung Cancer (SCLC)

Abstract CT164: Phase 1a/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid tumors (NCT06132503)

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Abstract 606: The PLK1 inhibitor, onvansertib, synergizes with paclitaxel in small cell lung cancer

P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

Abstract 1258: Preclinical Characterization of LOXO-338, a Novel, Oral and Selective BCL2 Inhibitor

Abstract 301: Targeting the Anti-Apoptotic BCL-2 Family Protein Provides an Effective and Precise Therapeutic Strategy for NHL

Genomic Analysis of Small-Cell Lung Carcinomas: Discovery of a Candidate Stratification Biomarker for a Bcl-2 Inhibitor

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer

Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

The Efficacy and Safety Profile of Anlotinib with Etoposide Plus Cisplatin/carboplatin in Treatment-Naive Extensive-Stage Small Cell Lung Cancer(sclc) Patients: Results from a Phase II Single-Arm Trial.

Abstract 5550: QLS31904: An anti-DLL3/CD3 bispecific antibody for T cell immunotherapy of small cell lung cancer

Abstract 6392: Activity of HER2-and TROP2- antibody drug conjugates (ADCs) in small cell lung cancer (SCLC) models with SLFN11 as a predictive biomarker

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.

Abstract 3942: Novel BCL2 inhibitors with anti-lymphoma activity